Drugs that contain Copanlisib Dihydrochloride

1. Drug name - ALIQOPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(1 year, 7 months from now)

USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(7 years from now)

US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(9 years from now)

CN100384846C BAYER HEALTHCARE Fused Pyrrole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

CN1688582A BAYER HEALTHCARE Fused Pyrrole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

CN105254634A BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

CN105254634B BAYER HEALTHCARE 2, 3-Dihydro-Imidazo [1, 2-C] - Quinazoline Substituted Derivative Treating Hyperproliferative Disease And Angiogenesis-Related Disease
Dec, 2027

(5 years from now)

CN103649091B BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

CN103649091A BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

IN238818B BAYER HEALTHCARE A Fused Azolepyrimidine Compound
Sep, 2023

(11 months from now)

IN200500684P1 BAYER HEALTHCARE A Fused Azolepyrimidine Compound
Sep, 2023

(11 months from now)

IN200902840P1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

IN292844B BAYER HEALTHCARE Substituted 2,3- Dihydroimidazo[1,2- C]Quinazoline Compounds
Dec, 2027

(5 years from now)

EP2042504A1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP1549652B1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP1549652A1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP2042504B1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP2096919A1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

EP2096919A4 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

EP2096919B1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

EP2694508B1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

EP2694508A1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts Mar, 2032

(9 years from now)

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.